{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:53:27Z","timestamp":1791910407541,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["MCE2408"],"award-info":[{"award-number":["MCE2408"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.vaccine.2026.129206","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:52:44Z","timestamp":1790509964000},"page":"129206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and internal analytical validation of plaque reduction neutralization test for clinical trial application of Kyasanur forest disease virus vaccine"],"prefix":"10.1016","volume":"93","author":[{"given":"Deepak Y.","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima R.","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita M.","family":"Shete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeleksmy","family":"Mohandas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Mali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajen","family":"Lakra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Marathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Gadekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gajanan","family":"Sapkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya D.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2026.129206_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/2224-3151.206890","article-title":"Highly infectious tick-borne viral diseases: Kyasanur forest disease and Crimean-Congo haemorrhagic fever in India","volume":"3","author":"Mourya","year":"2014","journal-title":"WHO South-East Asia J Public Health"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129206_bb0010","first-page":"341","article-title":"Summary of preliminary report of investigations of the Virus Research Centre on an epidemic disease affecting forest villagers and wild monkeys of Shimoga District, Mysore","volume":"11","author":"Work","year":"1957","journal-title":"Indian J Med Sci"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129206_bb0015","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3201\/eid1509.080759","article-title":"Recent ancestry of Kyasanur Forest disease virus","volume":"15","author":"Mehla","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129206_bb0020","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3201\/eid1902.120544","article-title":"Kyasanur forest disease, India, 2011\u20132012","volume":"19","author":"Kasabi","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129206_bb0025","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3201\/eid1909.121884","article-title":"Spread of Kyasanur forest disease, Bandipur tiger reserve, India, 2012\u20132013","volume":"19","author":"Mourya","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129206_bb0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40249-015-0044-2","article-title":"New focus of Kyasanur Forest disease virus activity in a tribal area in Kerala, India, 2014","volume":"4","author":"Tandale","year":"2015","journal-title":"Infect Dis Poverty"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129206_bb0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jinf.2016.03.006","article-title":"Outbreak of Kyasanur forest disease (monkey fever) in Sindhudurg, Maharashtra State, India, 2016","volume":"72","author":"Awate","year":"2016","journal-title":"J Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129206_bb0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1029\/2018GH000164","article-title":"Historical expansion of Kyasanur forest disease in India from 1957 to 2017: a retrospective analysis","volume":"3","author":"Chakraborty","year":"2019","journal-title":"GeoHealth"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129206_bb0045","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4103\/ijmr.IJMR_532_21","article-title":"Experiences of Indian Council of Medical Research with tick-borne zoonotic infections: Kyasanur Forest disease & Crimean-Congo haemorrhagic fever in India with One Health focus","volume":"153","author":"Mourya","year":"2021","journal-title":"Indian J Med Res"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129206_bb0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/23744235.2023.2282042","article-title":"Clinical, epidemiological, and molecular investigation of Kyasanur forest disease from Karnataka state, India during 2018-2019","volume":"56","author":"Munivenkatappa","year":"2024","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.vaccine.2026.129206_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2025.105831","article-title":"Unravelling ecological factors influencing phylodynamics of Kyasanur Forest Disease in India","volume":"135","author":"Paladan","year":"2025","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.vaccine.2026.129206_bb0060","first-page":"152","article-title":"Field evaluation of formalin inactivated Kyasanur forest disease virus tissue culture vaccine in three districts of Karnataka state","volume":"99","author":"Dandawate","year":"1994","journal-title":"Indian J Med Res"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129206_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226141","article-title":"Kyasanur Forest disease vaccination coverage and its perceived barriers in Goa, India\u2014a mixed methods operational research","volume":"14","author":"Oliveira","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129206_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/v17081022","article-title":"Kyasanur Forest disease virus: epidemiological insights, pathogenesis, therapeutic strategies, and advances in vaccines and diagnostics","volume":"17","author":"Bohra","year":"2025","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129206_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13050449","article-title":"From antibodies to immunity: assessing correlates of flavivirus protection and cross-reactivity","volume":"13","author":"Flores","year":"2025","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129206_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41392-023-01389-5","article-title":"Standardized neutralization antibody analytical procedure for clinical samples based on the AQbD concept","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129206_bb0085","first-page":"447","article-title":"Growth kinetics of Kyasanur forest disease virus in mammalian cell lines and development of plaque reduction neutralization test","volume":"19","author":"Sarkale","year":"2019","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129206_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/diseases12010029","article-title":"Plaque reduction neutralization test (PRNT) accuracy in evaluating humoral immune response to SARS-CoV-2","volume":"12","author":"Horbach","year":"2024","journal-title":"Diseases"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129206_bb0095","first-page":"3125","article-title":"Ability to serologically confirm recent zika virus infection in areas with endemic dengue, 2016","volume":"55","author":"Hajj","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2026.129206_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100052","article-title":"New proteomic signatures to distinguish between Zika and Dengue infections","volume":"20","author":"Allgoewer","year":"2021","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129206_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s44298-025-00114-z","article-title":"Flavivirus infections and diagnostic challenges for dengue, West Nile and Zika viruses","volume":"3","author":"Madere","year":"2025","journal-title":"npj Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129206_bb0110","first-page":"477","article-title":"Optimization and validation of a plaque reduction neutralization test for detection of neutralizing antibodies against Japanese encephalitis virus","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2026.129206_bb0115","series-title":"ICH Q2 (R2): validation of analytical procedures. Method validation in pharmaceutical analysis: a guide to best practice","first-page":"351","author":"Ermer","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129206_bb0120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129206_bb0125","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"BeitragzurkollektivenBehandlungpharmakologischerReihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Naunyn-SchmiedebergsArchivf\u00fcrexperimentellepathologie und pharmakologie."},{"key":"10.1016\/j.vaccine.2026.129206_bb0130","series-title":"Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses","author":"World Health Organization","year":"2007"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129206_bb0135","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129206_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28700","article-title":"Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials","volume":"95","author":"Dia","year":"2023","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129206_bb0145","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3390\/pathogens10070840","article-title":"Reporter virus neutralization test evaluation for dengue and zika virus diagnosis in flavivirus endemic area","volume":"10","author":"Nunes","year":"2021","journal-title":"Pathogens"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129206_bb0150","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02548-21","article-title":"A high-throughput yellow fever neutralization assay","volume":"10","author":"Rasulova","year":"2022","journal-title":"Microbiol Spectrum"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:24:40Z","timestamp":1791908680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26010157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":30,"alternative-id":["S0264410X26010157"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129206","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and internal analytical validation of plaque reduction neutralization test for clinical trial application of Kyasanur forest disease virus vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129206"}}